Valentis Report issue

For profit Phase 2
Founded: Pleasantville NJ United States (2013)
Status: Acquired by Urigen (2007)

Organization Overview

First Clinical Trial
None
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2005

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (2)

vepoloxamer (1 trial)

vlts-589 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Intermittent Claudication (Phase 2)

Peripheral Arterial Disease (Phase 2)

Peripheral Vascular Diseases (Phase 2)

Vascular Diseases (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2